Epstein Secrets

ing on `unsustainable drug prices' concludes — Hybrid hearing on `Unsustainable Drug Prices: Testimony from the CEOs (Part II)', with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM * Tom Lantos Human

mony from Commodity Futures Trading Commission Commissioner Rostin Behnam; Fermat Capital Management Senior Underwriter and Director of New Markets Joanna Syroka; Environmental Defense Fund Director of Working Lands Maggie Monast; and ClearPath Executive Director Rich Powell; 1:00 PM Cabinet Officers: * Tre

ring on `unsustainable drug prices' concludes - Hybrid hearing on Unsustainable Drug Prices: Testimony from the CEOs (Part II); with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human

mony from Commodity Futures Trading Commission Commissioner Rostin Behnam; Fermat Capital Management Senior Underwriter and Director of New Markets Joanna Syroka; Environmental Defense Fund Director of Working Lands Maggie Monast; and ClearPath Executive Director Rich Powell; 1:00 PM Cabinet Officers: EFTA0

ng on 'unsustainable drug prices' concludes - Hybrid hearing on 'Unsustainable Drug Prices: Testimony from the CEOs (Part II)', with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human

dity Futures Trading Commission Commissioner Rostin Behnam; Fermat Capital Management Senior Underwriter and Director EFTA01658536 of New Markets Joanna Syroka; Environmental Defense Fund Director of Working Lands Maggie Monast; and ClearPath Executive Director Rich Powell; 1:00 PM Cabinet Officers: • Tre